Results 171 to 180 of about 5,062,336 (201)
Some of the next articles are maybe not open access.

BRAFV600E Mutation Does Not Significantly Affect the Efficacy of Radioiodine Therapy in Patients With Papillary Thyroid Carcinoma Without Known Distant Metastases

Clinical Nuclear Medicine, 2018
Purpose The BRAFV600E mutation is the most common and specific oncogenic event in papillary thyroid carcinoma (PTC). However, its role in radioiodine therapy decision making has yet to be established.
G. Shen   +4 more
semanticscholar   +1 more source

Radioiodine Therapy of Thyroid Cancer

Nuclear Medicine Therapy, 2019
F. Verburg
semanticscholar   +1 more source

Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians

Ca-A Cancer Journal for Clinicians, 2022
William A Hal, X Allen Li, Daniel A Low
exaly  

Radioiodine Therapy.

Seminars in nuclear medicine, 2017
M. Luster   +3 more
semanticscholar   +1 more source

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen   +2 more
exaly  

Radiation therapy‐associated toxicity: Etiology, management, and prevention

Ca-A Cancer Journal for Clinicians, 2021
Kyle Wang
exaly  

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

Journal of Clinical Endocrinology and Metabolism, 2006
C. Durante   +10 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy